Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 83, Issue 9, 2012, Pages 927-933

  Mentzer, Dirk ^a   Prestel, Jürgen ^a   Adams, Ortwin ^b   Gold, Ralf ^c   Hartung, Hans Peter ^b   Hengel, Hartmut ^b   Kieseier, Bernd C ^b   Ludwig, Wolf Dieter ^d   Keller Stanislawski, Brigitte ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c ST JOSEF HOSPITAL   (Germany)

^d HELIOS Clinic Berlin Buch   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BRENTUXIMAB VEDOTIN; EFALIZUMAB; GADOLINIUM; MONOCLONAL ANTIBODY; NATALIZUMAB; OFATUMUMAB; PROTEIN VP1; RITUXIMAB; VIRUS DNA; VIRUS LARGE T ANTIGEN;

ADULT; AGED; ALGORITHM; APHASIA; ARTICLE; ATAXIA; AUTOPSY; BEHAVIOR CHANGE; BRAIN BIOPSY; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; CONFUSION; CONTRAST ENHANCEMENT; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISORIENTATION; DRUG INDICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSARTHRIA; FEMALE; HEMIANOPIA; HEMIPARESIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; JC VIRUS; LANGUAGE DISABILITY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL HEALTH; MOOD CHANGE; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MYOCLONUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALITY DISORDER; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SEIZURE; SENSORY DYSFUNCTION; SIDE EFFECT; SPEECH DISORDER; STANDARDIZATION; VISUAL DISORDER;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIBODIES, MONOCLONAL; BRAIN; DIAGNOSTIC TECHNIQUES, NEUROLOGICAL; DNA, VIRAL; FEMALE; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; MALE;

EID: 84864824084     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-302478     Document Type: Article

References (25)

1. Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009;199:837-46.
2. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010;68:295-303.
3. Delbue S, Branchetti E, Bertolacci S, et al. JC virus VP1 loop-specific polymorphisms are associated with favorable prognosis for progressive multifocal leukoencephalopathy. J Neurovirol 2009; 15:51-6.
4. Berger JR, Houff SA, Major EO. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs 2009; 1:583-9.
5. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-40.
6. Jalan P, Mahajan A, Pandav V, et al. Brentuximab associated progressive multifocal leukoencephalopathy. Clin Neurol Neurosurg . Published Online First: 1 April 2012. doi:10.1016/j.clineuro.2012.03.019
7. Brew BJ, Davies NW, Cinque P, et al. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 2010;6 :667-79.
8. Yokoyama H, Watanabe T, Maruyama D, et al. Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature. Int J Hematol 2008;88:443-7.
9. Vinhas de Souza M, Keller-Stanislawski B, Blake K, et al. Drug-induced PML: a global agenda for a global challenge. Clin Pharmacol Ther 2012;91:747-50.
10. Kohl KS, Bonhoeffer J, Braun MM, et al. The Brighton Collaboration: creating a global standard for case definitions (and guidelines) for adverse events following immunization. In: Henriksen K, Battles JB, Marks ES, et al, eds. Advances in patient safety: from Research to Implementation (Volume 2: Concepts and Methodology). Rockville, MD: Agency for healthcare research and quality (US), 2005:87-102.
11. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Maintenance of the ICH guideline on clinical safety data management: data elements for transmission of individual case safety reports E2B(R2). 2001:1- 25. http://www.ich.org/ fileadmin/Public-Web-Site/ ICH-Products/Guidelines/Efficacy/E2B/Step4/E2B-R2- Guideline.pdf (accessed 24 Apr 2012).
12. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010;9 :425-37.
13. Clifford DB, DeLuca A, Simpson DM, et al. Natalizumab- associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9:438-46.
14. Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011;68:1156-64.
15. Kothary N, Diak IL, Brinker A, et al. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 2011;65:546-51.
16. Schwab N, Ulzheimer JC, Fox RJ, et al. Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control. Neurology 2012;78:458-67.
17. Biogen Idec. [Physician Information]. 2010:16-17. http://tysabri.de/ index.php? inhalt=tysabri.sicherheitsmanagement (accessed 7 Feb 2012).
18. Shah R, Bag AK, Chapman PR, et al. Imaging manifestations of progressive multifocal leukoencephalopathy. Clin Radiol 2010;65:431-9.
19. Cinque P, Koralnik IJ, Gerevini S, et al . Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis 2009;9:625-36.
20. Metz I, Radue EW, Oterino A, et al. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol 2012;123:235-45.
21. Tan K, Roda R, Ostrow L, et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009;72:1458-64.
22. Kuhle J, Gosert R, Bühler R, et al. Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology 2011;77:2010-16.
23. Hellwig K, Gold R. Progressive multifocal leukoencephalopathy and natalizumab. J Neurol 2011; 258:1920-8.
24. Iacobaeus E, Ryschkewitsch C, Gravell M, et al. Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA. Mult Scler 2009;15:28-35.
25. Tan CS, Ellis LC, Wüthrich C, et al. JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy. J Virol 2010;84:9200-9.